Who are Metformin and FSHr's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-and-fshr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metformin and FSHr — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin and FSHr (Metformin and FSHr) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: biguanide + gonadotropin receptor agonist. Area: Reproductive endocrinology / Fertility / Metabolic disorders.

marketed Combination therapy: biguanide + gonadotropin receptor agonist Metformin: mitochondrial glycerophosphate dehydrogenase; FSHr: follicle-stimulating hormone receptor Reproductive endocrinology / Fertility / Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

Metformin and FSHr (Metformin and FSHr) — Assistance Publique - Hôpitaux de Paris. This combination uses metformin to improve insulin sensitivity and metabolic parameters while FSHr (follicle-stimulating hormone receptor) agonism promotes follicular development for fertility enhancement.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin and FSHr TARGET	Metformin and FSHr	Assistance Publique - Hôpitaux de Paris	marketed	Combination therapy: biguanide + gonadotropin receptor agonist	Metformin: mitochondrial glycerophosphate dehydrogenase; FSHr: follicle-stimulating hormone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: biguanide + gonadotropin receptor agonist class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin and FSHr — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-and-fshr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab